Vertex Pharmaceuticals Inc

NASDAQ: VRTX

  • Vertex Pharmaceuticals Inc
  • Sector

    Health Care
  • Industry

  • Company web

    Link
  • Employees

    Full Time Employees: 2,150
  • Executives

    • Jeffrey Leiden
    • Thomas Graney
    • Ian Smith
    • Michael Parini
    • David Altshuler
    • Stuart Arbuckle
    • Jeffrey Chodakewitz
    • Amit Sachdev
    • Paul Silva
    • Bruce Sachs
  • Company address

    • 50 Northern Avenue
    • Boston, MA 02210
    • United States of America
    • 1-617-341-6100
  • Investor Relation Site

    Link

Vertex Pharmaceuticals Incorporated discovers, develops, manufactures, and commercializes medicines for serious diseases. The company focuses on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs. It markets ORKAMBI (lumacaftor in combination with ivacaftor) for the treatment of patients with CF 12 years of age and older who have two copies (homozygous) of the F508del mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene; and KALYDECO (ivacaftor) for the treatment of patients with CF 2 years of age and older who have the G551D mutation or other specified mutations in their CFTR gene. The company also develops Tezacaftor (VX-661), a corrector compound that is in a Phase III development program in combination with ivacaftor in multiple CF patients; VX-152 and VX-440 that are CFTR corrector compounds in Phase II clinical trials, as well as VX-659 and VX-445 that are CFTR corrector compounds in Phase I clinical trials; and VX-371, an investigational epithelial sodium channel, which is in a Phase II development program. In addition, it engages in the research and mid-and early-stage development programs in the areas of oncology, pain, and neurology. The company sells its products primarily to specialty pharmacy providers and wholesalers in North America, as well as government-owned and supported customers internationally. Vertex Pharmaceuticals Incorporated has collaborations with Cystic Fibrosis Foundation Therapeutics Incorporated; Parion Sciences, Inc.; CRISPR Therapeutics AG; Moderna Therapeutics, Inc.; BioAxone Biosciences, Inc.; Merck KGaA; and Janssen Pharmaceuticals, Inc. The company was founded in 1989 and is headquartered in Boston, Massachusetts.

Vertex Pharmaceuticals Inc: Slide deck

  • VRTX-Third-Quarter 2017 Financial Results October 2017: Slides deck
  • VRTX-Third Quarter 2016 Financial Results October 25, 2016: Slides deck
  • VRTX-Second-Quarter 2017 Financial Results July 2017: Slides deck
  • VRTX-First-Quarter 2017 Financial Results April 2017: Slides deck
  • VRTX-Full-Year and Fourth-Quarter 2016 Financial Results January 2017: Slides deck

Related companies

Teva Pharmaceutical Industries Limited

Health Care

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic...

Sanofi

Health Care

Sanofi researches, develops, manufactures, and markets therapeutic solutions. The company operates in two segments, Pharmaceuticals and Vaccines. It offers Cerezyme and Cerdelga for Gaucher...

Smith & Nephew SNATS Inc

Health Care

Smith & Nephew plc designs, develops, and sells medical devices worldwide. The company offers sports medicine joint repair products for surgeons, including an array...

Shire plc

Health Care

Shire plc, a biotechnology company, focused on serving people with rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas,...

Koninklijke Philips NV

Health Care

Koninklijke Philips N.V. operates as a health technology company worldwide. It offers diagnostic imaging solutions, magnetic resonance imaging, computed tomography, and diagnostic X-ray; advanced...

Novartis AG

Health Care

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company’s Innovative Medicines segment offers patented prescription medicines to enhance health outcomes for...